Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASH 2015 | Improving patient outcomes in acute lymphoblastic leukemia at ASH 2015

Ryan Cassaday • 4 Dec 2015
ASH 2015
Acute Lymphoblastic Leukemia Antibodies Blinatumomab Rituximab

Ryan Cassaday, MD, from Fred Hutchinson Cancer Research Center, Seattle, WA, discusses clinical data presented on acute lymphoblastic leukemia (ALL) at the 58th American Society of Hematology (ASH) Annual Meeting & Exposition. Highlights include a clinical trial evaluating rituximab, an anti-CD20 monoclonal antibody, added to a chemotherapy backbone; a phase 2 clinical trial of blinatumomab, a bispecific single-chain antibody targeting the CD19 antigen; and early clinical trials evaluating CD19-targeted chimeric antigen receptor (CAR) T-cell therapy.

More from Ryan Cassaday

2:42
Blinatumomab's place in the ALL treatment landscape
Ryan Cassaday • 20 Jun 2022
2:39
The future of immunotherapy for the treatment of ALL
Ryan Cassaday • 20 Jun 2022
2:48
Results from a subgroup analysis of ZUMA-3 and the efficacy of brexu-cel in R/R B-ALL
Ryan Cassaday • 20 Jun 2022
3:01
Dose-adjusted EPOCH plus inotuzumab ozogamicin for B-ALL
Ryan Cassaday • 20 Jun 2022

Related Videos

2:06
Managing relapsed ALL: the role of novel cellular therapies & importance of conditioning regimens
Christina Peters • 15 Apr 2024
1:48
Do all patients require maintenance therapy following alloSCT?
Mark Levis • 16 Apr 2024
1:15
Comparing the efficacy of salvage therapies in adult B-ALL: a retrospective real-world study
Alex Rampotas • 16 Apr 2024
3:34
Total marrow and lymphoid irradiation plus cyclophosphamide & etoposide in poor-risk acute leukemias
Anthony Stein • 15 Apr 2024
The content of VJHemOnc is intended for healthcare professionals